HRSA Seeks Increased Pricing Transparency For Safety Net Drug Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
The Health Resources & Services Administration is exploring ways to ensure accuracy of discounted drug prices given to providers under the 340B program. HRSA does not plan to seek legislative authority to penalize manufacturers that violate the 340B pricing agreement.